What is Pion?
Founded in the United States with research roots tracing back to 1989, Pion operates from Billerica, Massachusetts. The company specializes in providing cutting-edge technology, comprehensive solutions, dedicated support, and scientific expertise to the drug development industry. Pion empowers pharmaceutical researchers by delivering trusted data through a suite of novel testing instruments and techniques. A key component of their offering is the Rainbow in situ fiber-optics UV measurement instrument, a technology acquired through the purchase of Delphian Technology in 2002. The company was acquired by Mike and Sharon Kelly in 2011, further solidifying its commitment to innovation in creating products that impact people's lives.
How much funding has Pion raised?
Pion has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Pion
PPP
Public-Private Partnership
What's next for Pion?
With a substantial total funding amount of $350K and a recent strategic investment of $350K, Pion is well-positioned for its next phase of growth. This large-scale, late-stage funding suggests a focus on scaling operations, expanding market reach, and potentially accelerating the development and commercialization of its innovative drug development technologies. The company's trajectory indicates a strong market validation and investor confidence in its ability to continue making significant contributions to the pharmaceutical research community.
See full Pion company page
